Creative Medical Technology (CELZ) Stock Price, News & Analysis

Company Overview

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Key Stats

• Today's Range: $2.90 to $3.58
• 50-Day Range: $2.14 to $6.45
• 52-Week Range: $1.96 to $6.90
• Volume: 155,446 shs
• Average Volume: 36,768 shs
• Market Capitalization: $6.97 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Creative Medical Technology Stock Analysis - MarketRank™

Creative Medical Technology scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Creative Medical Technology.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Creative Medical Technology are expected to grow in the coming year, from ($3.19) to ($2.24) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Creative Medical Technology is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Creative Medical Technology is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Creative Medical Technology has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.81% of the float of Creative Medical Technology has been sold short.

Short Interest Ratio / Days to Cover

Creative Medical Technology has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Creative Medical Technology has recently increased by 88.10%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Creative Medical Technology does not currently pay a dividend.

Dividend Growth

Creative Medical Technology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.81% of the float of Creative Medical Technology has been sold short.

Short Interest Ratio / Days to Cover

Creative Medical Technology has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Creative Medical Technology has recently increased by 88.10%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.32

News Sentiment

Creative Medical Technology has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Creative Medical Technology this week, compared to 0 articles on an average week.

Search Interest

9 people have searched for CELZ on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Creative Medical Technology to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Creative Medical Technology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,750.00 in company stock.

Percentage Held by Insiders

Only 2.80% of the stock of Creative Medical Technology is held by insiders.

Percentage Held by Institutions

Only 1.42% of the stock of Creative Medical Technology is held by institutions.

CELZ Stock Analysis - Frequently Asked Questions

How have CELZ shares performed this year?

Creative Medical Technology's stock was trading at $2.31 at the start of the year. Since then, CELZ shares have increased by 29.9% and is now trading at $3.00.
View the best growth stocks for 2025 here.

How were Creative Medical Technology's earnings last quarter?

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) posted its earnings results on Friday, August, 9th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.84) by $0.27. The company had revenue of $0.01 million for the quarter.

When did Creative Medical Technology's stock split?

Creative Medical Technology's stock reverse split before market open on Sunday, June 11th 2023. The 1-10 reverse split was announced on Sunday, June 11th 2023. The number of shares owned by shareholders was adjusted after the market closes on Sunday, June 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Creative Medical Technology's major shareholders?

Creative Medical Technology's top institutional investors include Geode Capital Management LLC (0.59%). Insiders that own company stock include Timothy Warbington and Michael H Finger.
View institutional ownership trends.

How do I buy shares of Creative Medical Technology?

Shares of CELZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Creative Medical Technology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Creative Medical Technology investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), FuelCell Energy (FCEL), Tesla (TSLA), NVIDIA (NVDA), PayPal (PYPL) and ChargePoint (CHPT).

Company Calendar

• Last Earnings: 8/09/2024
• Today: 3/13/2025
• Next Earnings (Estimated): 3/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CELZ
• CIK: 1187953
• Web: www.creativemedicaltechnology.com
• Phone: (833) 336-7636
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($3.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-5,290,000.00
• Net Margins: N/A
• Pretax Margin: -48,354.54%
• Return on Equity: -63.05%
• Return on Assets: -60.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.13
• Quick Ratio: 19.12

Sales & Book Value

• Annual Sales: $11,000.00
• Price / Sales: 633.55
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.48 per share
• Price / Book: 0.40

Miscellaneous

• Outstanding Shares: 2,323,000
• Free Float: 1,699,000
• Market Cap: $6.97 million
• Optionable: Not Optionable
• Beta: 1.70